Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Nissan Chemical has revealed positive results from its phase IIb study of its investigational drug NM-702 for the treatment of intermittent claudication, a symptom of peripheral arterial disease characterized by exercise-induced lower extremity pain and muscle fatigue.
Subscribe to our email newsletter
The study enrolled 391 patients, who were assessed after six months of therapy. Results from the study showed NM-702 was associated with a statistically significant increase in patients’ peak walking time as compared with placebo, the study’s primary endpoint. Secondary endpoints were also supportive of NM-702 efficacy, the company said.
“We intend to submit the final results of the study to the FDA as one of our initial pivotal trials for NDA, and are optimistic these data will guide the successful completion of NM-702 development for this indication.” stated Dr Isao Koda, general manager of Nissan Chemical’s US operation.
Nissan Chemical is currently partnered with Taisho Pharmaceuticals for the joint development of NM-702 in Japan, and support for further studies in the US to accelerate the global commercialization of this product. Taisho is currently investigating NM-702 in clinical trials for intermittent claudication and asthma in Japan.